Maze Shares Jump As Investors Bet Big On Experimental Treatment’s Potential

All NewsSeptember 11, 2025

Maze’s MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and no serious side effects.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent